FERRITIN NANOCAGE FUSED WITH PD-L1-BINDING PEPTIDE 1 AND USE THEREOF AS ANTICANCER IMMUNOTHERAPY AGENT

The present invention relates to a ferritin nanocage fused with PD-L1-binding peptide 1 and a use thereof as an anticancer immunotherapy agent. Prepared in the present invention were nanocages that are formed by fusing a human ferritin monomer with a peptide 1 (PD-L1pep1: CLQKTPKQC) binding to the i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KIM, Min-Seong, LEE, Byung-Heon, YOO, Jae Do, KIM, Soyoun, JEON, In Seon
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	KIM, Min-Seong LEE, Byung-Heon YOO, Jae Do KIM, Soyoun JEON, In Seon
description	The present invention relates to a ferritin nanocage fused with PD-L1-binding peptide 1 and a use thereof as an anticancer immunotherapy agent. Prepared in the present invention were nanocages that are formed by fusing a human ferritin monomer with a peptide 1 (PD-L1pep1: CLQKTPKQC) binding to the immune checkpoint receptor PD-L1 overexpressed in many cancers such as breast cancer, colorectal cancer, renal cancer, glioblastoma, etc. and which display 24 Pd-L1prep1. The nanocages of the present invention effectively target colorectal cancer tissues to exhibit an anticancer effect. When loading the anticancer agent doxorubicin thereinto, the nanocages showed higher anticancer effects than the same dose of PD-L1 antibody. Accordingly, the nanocages are expected as a next-generation drug that surmounts the limitation of immune checkpoint blocking therapy using antibodies.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP4234578A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP4234578A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP4234578A13</originalsourceid><addsrcrecordid>eNqNjMEKgkAQhr10iOod5gU8mEZdp91ZHchxWUeik0ispyjB3p8MeoBOP3zfx79ORkchsLKAoDQGSwLXtWThylqBt-klS88slqUET17ZEmSAYmGpQCsK1DjAdkHKBsVQAK7rTpqvQ3-D5VJ0m6zG4THH3W83CThSU6VxevVxnoZ7fMZ3T77Y58XheMIs_yP5APmqNCU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FERRITIN NANOCAGE FUSED WITH PD-L1-BINDING PEPTIDE 1 AND USE THEREOF AS ANTICANCER IMMUNOTHERAPY AGENT</title><source>esp@cenet</source><creator>KIM, Min-Seong ; LEE, Byung-Heon ; YOO, Jae Do ; KIM, Soyoun ; JEON, In Seon</creator><creatorcontrib>KIM, Min-Seong ; LEE, Byung-Heon ; YOO, Jae Do ; KIM, Soyoun ; JEON, In Seon</creatorcontrib><description>The present invention relates to a ferritin nanocage fused with PD-L1-binding peptide 1 and a use thereof as an anticancer immunotherapy agent. Prepared in the present invention were nanocages that are formed by fusing a human ferritin monomer with a peptide 1 (PD-L1pep1: CLQKTPKQC) binding to the immune checkpoint receptor PD-L1 overexpressed in many cancers such as breast cancer, colorectal cancer, renal cancer, glioblastoma, etc. and which display 24 Pd-L1prep1. The nanocages of the present invention effectively target colorectal cancer tissues to exhibit an anticancer effect. When loading the anticancer agent doxorubicin thereinto, the nanocages showed higher anticancer effects than the same dose of PD-L1 antibody. Accordingly, the nanocages are expected as a next-generation drug that surmounts the limitation of immune checkpoint blocking therapy using antibodies.</description><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230830&DB=EPODOC&CC=EP&NR=4234578A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25544,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230830&DB=EPODOC&CC=EP&NR=4234578A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KIM, Min-Seong</creatorcontrib><creatorcontrib>LEE, Byung-Heon</creatorcontrib><creatorcontrib>YOO, Jae Do</creatorcontrib><creatorcontrib>KIM, Soyoun</creatorcontrib><creatorcontrib>JEON, In Seon</creatorcontrib><title>FERRITIN NANOCAGE FUSED WITH PD-L1-BINDING PEPTIDE 1 AND USE THEREOF AS ANTICANCER IMMUNOTHERAPY AGENT</title><description>The present invention relates to a ferritin nanocage fused with PD-L1-binding peptide 1 and a use thereof as an anticancer immunotherapy agent. Prepared in the present invention were nanocages that are formed by fusing a human ferritin monomer with a peptide 1 (PD-L1pep1: CLQKTPKQC) binding to the immune checkpoint receptor PD-L1 overexpressed in many cancers such as breast cancer, colorectal cancer, renal cancer, glioblastoma, etc. and which display 24 Pd-L1prep1. The nanocages of the present invention effectively target colorectal cancer tissues to exhibit an anticancer effect. When loading the anticancer agent doxorubicin thereinto, the nanocages showed higher anticancer effects than the same dose of PD-L1 antibody. Accordingly, the nanocages are expected as a next-generation drug that surmounts the limitation of immune checkpoint blocking therapy using antibodies.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjMEKgkAQhr10iOod5gU8mEZdp91ZHchxWUeik0ispyjB3p8MeoBOP3zfx79ORkchsLKAoDQGSwLXtWThylqBt-klS88slqUET17ZEmSAYmGpQCsK1DjAdkHKBsVQAK7rTpqvQ3-D5VJ0m6zG4THH3W83CThSU6VxevVxnoZ7fMZ3T77Y58XheMIs_yP5APmqNCU</recordid><startdate>20230830</startdate><enddate>20230830</enddate><creator>KIM, Min-Seong</creator><creator>LEE, Byung-Heon</creator><creator>YOO, Jae Do</creator><creator>KIM, Soyoun</creator><creator>JEON, In Seon</creator><scope>EVB</scope></search><sort><creationdate>20230830</creationdate><title>FERRITIN NANOCAGE FUSED WITH PD-L1-BINDING PEPTIDE 1 AND USE THEREOF AS ANTICANCER IMMUNOTHERAPY AGENT</title><author>KIM, Min-Seong ; LEE, Byung-Heon ; YOO, Jae Do ; KIM, Soyoun ; JEON, In Seon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP4234578A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>KIM, Min-Seong</creatorcontrib><creatorcontrib>LEE, Byung-Heon</creatorcontrib><creatorcontrib>YOO, Jae Do</creatorcontrib><creatorcontrib>KIM, Soyoun</creatorcontrib><creatorcontrib>JEON, In Seon</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KIM, Min-Seong</au><au>LEE, Byung-Heon</au><au>YOO, Jae Do</au><au>KIM, Soyoun</au><au>JEON, In Seon</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FERRITIN NANOCAGE FUSED WITH PD-L1-BINDING PEPTIDE 1 AND USE THEREOF AS ANTICANCER IMMUNOTHERAPY AGENT</title><date>2023-08-30</date><risdate>2023</risdate><abstract>The present invention relates to a ferritin nanocage fused with PD-L1-binding peptide 1 and a use thereof as an anticancer immunotherapy agent. Prepared in the present invention were nanocages that are formed by fusing a human ferritin monomer with a peptide 1 (PD-L1pep1: CLQKTPKQC) binding to the immune checkpoint receptor PD-L1 overexpressed in many cancers such as breast cancer, colorectal cancer, renal cancer, glioblastoma, etc. and which display 24 Pd-L1prep1. The nanocages of the present invention effectively target colorectal cancer tissues to exhibit an anticancer effect. When loading the anticancer agent doxorubicin thereinto, the nanocages showed higher anticancer effects than the same dose of PD-L1 antibody. Accordingly, the nanocages are expected as a next-generation drug that surmounts the limitation of immune checkpoint blocking therapy using antibodies.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; fre ; ger
recordid	cdi_epo_espacenet_EP4234578A1
source	esp@cenet
subjects	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
title	FERRITIN NANOCAGE FUSED WITH PD-L1-BINDING PEPTIDE 1 AND USE THEREOF AS ANTICANCER IMMUNOTHERAPY AGENT
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A51%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KIM,%20Min-Seong&rft.date=2023-08-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP4234578A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true